Read more
There are many conditions that affect the skeletal system. On a worldwide basis, osteoarthritis alone affects 10%-15 percent of those over 60 years of age and in some countries more than 30-50% of postmenopausal women will have osteopenia or osteoporosis. With the increasing ageing population, maintaining skeletal health is particularly important. Fractures in the aged, for example, can lead to premature deaths. It is therefore imperative that appropriate use is made of conventional, new and emerging biomarker platforms. Biomarkers in Bone Disease embraces a holistic approach by combining information on different conditions that affect the skeletal system and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge, trends and innovations. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.
List of contents
Serum uric acid and biomarkers of lumbar spine bone mineral density.- Use of alkaline phosphatase (ALP) activity and disease severity to determine secular changes in bone disease as applied to Paget's disease of the bone.- Bone Turnover and Spinal Cord Injury.- Bone-related proteins as markers in vascular remodelling.- Serum Sclerostin as Biomarker in Osteogenesis Imperfecta.- Parathyroid Hormone (PTH) assays and applications to bone disease: Overview on methodology.- Registered microcomputed tomography data as a four dimensional imaging biomarker of bone formation and resorption.- Use of bone biomarkers after weight loss: Example of bariatric surgery.- Adiponectin as biomarker of osteoporosis.- Effect of statins on bone turnover markers.- Chitinases as biomarkers in bone studies.- Hormone relaxin as biomarker for bone health and disease.- Panoramic radiomorphometric indices of mandible: Biomarker for osteoporosis.- Hip Fracture Risk is Strongly Related to Circulating Levels of the Advanced Glycation End-product Carboxy-Methyl Lysine (CML).- Effects of glucose on bone markers: Overview of current knowledge with focus on diabetes, glucose, and bone markers.- Traditional medicine and use of bone biomarkers.- Osteosarcoma Biomarkers discovery using "omics" approaches.- Creatine kinase as biomarker in osteogenesis imperfecta.- Ameloblastin as biomarker of bone.- Biomarker genes in autosomal dominant osteopetrosis type II (ADO II).- Bone markers in Rett syndrome.- Bone Specific Alkaline Phosphatase and Exercise.- Bone turnover markers and glucocorticoid treatments.- Overview of biochemical markers of bone metabolism.- Biomarkers of natural radionuclides in bone and teeth.- Bone markers throughout sexual development: epidemiological significance and population-based findings.- Parathyroid hormone (PTH) and the relationship between PTH and bone health: structure, physiology, actions, and ethnicity.- Quantitative ultrasound as a biomarker tool in newborn infants for bone.-Bone biomarkers in gestational hypertension.- Bone biomarkers in intrauterine growth restriction.- Raman spectroscopy as a biomarker-investigative tool in bone metabolism.- Pentosidine as a biomarker for poor bone quality and elevated fracture risk.- Spine bone texture and the trabecular bone score (TBS).- Bone biomarkers in HIV.- Bone Biomarkers Related to Osteoarthritis.- Dietary Soy Phytoestrogens and Biomarkers of Osteoporosis.- Utilisation and reference values of osteocalcin and procollagen type 1 n-propeptide.- Analysis of integrin alpha2beta1 (a2b1) expression as a biomarker of skeletal metastasis.- Circulating Sclerostin in Bone Sclerosing Disorders.- Pentraxin 3 as a bone biomarker.- Sirtuins as markers of bone disease: a focus on osteoarthritis and osteoporosis.- Tartarate resistant acid phosphatase as a biomarker of bone remodeling.
About the author
Professor Victor R. Preedy is a senior faculty member of King's College London (Professor of Nutritional Biochemistry) and King's College Hospital (Professor of Clinical Biochemistry). He is attached to both the Diabetes and Nutritional Sciences Division and the Department of Nutrition and Dietetics. He is also Director of the Genomics Centre and a member of the School of Medicine. Professor Preedy graduated in 1974 with an Honours Degree in Biology and Physiology with Pharmacology. He gained his University of London PhD in 1981. In 1993 he gained his second doctoral degree, for his outstanding contribution to protein metabolism in health and disease. He has received membership and fellowship of a number of academic and professional bodies in the UK, including the Royal College of Pathologists, the Royal Institute of Public Health, and the Royal Society of Chemistry. Professor Preedy has published over 570 articles, which includes 165 peer-reviewed manuscripts based on original research, 100 reviews, and over 50 books and book volumes.
Summary
There are many conditions that affect the skeletal system. On a worldwide basis, osteoarthritis alone affects 10%-15 percent of those over 60 years of age and in some countries more than 30-50% of postmenopausal women will have osteopenia or osteoporosis. With the increasing ageing population, maintaining skeletal health is particularly important. Fractures in the aged, for example, can lead to premature deaths. It is therefore imperative that appropriate use is made of conventional, new and emerging biomarker platforms. Biomarkers in Bone Disease embraces a holistic approach by combining information on different conditions that affect the skeletal system and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge, trends and innovations. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.
